单位:[1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital National Clinical Research Center for Respiratory Diseases. Beijing, China 100029[2]Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Introduction: Myofibroblasts are the primary executor and influencer in lung fibrosis. Latest studies on lung myofibroblast pathobiology have significantly advanced the understanding of the pathogenesis of lung fibrosis and shed new light on strategies targeting these cells to treat this disease. Areas covered: This article reviewed the most recent progresses, mainly within the last 5 years, on the definition, origin, activity regulation, and targeting of lung myofibroblasts in lung fibrosis. We did a literature search on PubMed using the keywords below from the dates 2010 to 2020. Expert opinion: With the improved cell lineage characterization and the advent of scRNA-seq, the field is having much better picture of the lung myofibroblast origin and mesenchymal heterogeneity. Additionally, cellular metabolism has emerged as a key regulation of lung myofibroblast pathogenic phenotype and is a promising therapeutic target for treating a variety of lung fibrotic disorders.
基金:
NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL135830]; Department of DefenseUnited States Department of Defense [W81XWH-20-1-0226]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81700067, 81870056]
第一作者单位:[1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital National Clinical Research Center for Respiratory Diseases. Beijing, China 100029
通讯作者:
通讯机构:[2]Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.[*1]Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 901 19th St. So., BMR II 233, Birmingham, Alabama 35294, USA
推荐引用方式(GB/T 7714):
Jiang Dingyuan,Dey Tapan,Liu Gang.Recent developments in the pathobiology of lung myofibroblasts[J].EXPERT REVIEW of RESPIRATORY MEDICINE.2021,15(2):239-247.doi:10.1080/17476348.2021.1829972.
APA:
Jiang, Dingyuan,Dey, Tapan&Liu, Gang.(2021).Recent developments in the pathobiology of lung myofibroblasts.EXPERT REVIEW of RESPIRATORY MEDICINE,15,(2)
MLA:
Jiang, Dingyuan,et al."Recent developments in the pathobiology of lung myofibroblasts".EXPERT REVIEW of RESPIRATORY MEDICINE 15..2(2021):239-247